Karuna’s schizophrenia drug clears another PhIII as biotech seeks 2024 launch
Karuna Therapeutics said its investigational schizophrenia treatment cleared the bar in another Phase III clinical trial, which the biotech hopes will open the doors for a new class of medication for the millions of people living with the disorder as it tees up a mid-2023 approval request.
The Boston biotech’s KarXT drug showed a statistically significant and clinically meaningful reduction in symptoms compared to placebo on the main study goal in patients with schizophrenia, Karuna said before Monday’s opening bell. The design of the 256-patient Phase III EMERGENT-3 was essentially a “carbon copy” of the company’s two other Phase III and Phase II studies of the drug, CEO and president Bill Meury told Endpoints News on Sunday afternoon, in a preview of the data drop.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters